News | April 15, 2025
Biocon Biologics secures market entry date for Yesafili in US
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
Theatre (OTs) dedicated to cataract, LASIK, and retina treatments added to meet the growing demand
Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME)
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
Spread over 1.26 lakh sq ft building, the super-specialty eye hospital will perform 30,000 free eye surgeries annually for economically weaker sections
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
These gummies are specially formulated for both kids and adults to nourish the eyes and promote optimal vision development
Susvimo is a unique therapeutic approach that provides continuous delivery of medicine to the eye through a refillable implant
Subscribe To Our Newsletter & Stay Updated
